Univ. Health Network-Princess Margaret Hospital
Welcome,         Profile    Billing    Logout  
 22 Trials 
38 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wong, Rebecca
NCT05661409: Sugammadex as Rescue Therapy

Completed
4
71
US
Sugammadex, Placebo
Emory University, National Center for Advancing Translational Sciences (NCATS), Georgia Clinical & Translational Science Alliance (CTSA)
Neuromuscular Blockade
08/24
08/24
NCT04084548: Perioperative Lidocaine and Ketamine in Abdominal Surgery

Active, not recruiting
3
420
US
Lidocaine and ketamine, Lidocaine, Ketamine, Placebo
The Cleveland Clinic
Postoperative Pain
12/24
12/24
TALES, NCT03011684: Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial

Recruiting
3
144
US
Tamoxifen, Letrozole
University of California, San Francisco
Infertility
01/25
01/25
NatPro, NCT04551807: Natural Versus Programmed Frozen Embryo Transfer

Active, not recruiting
3
788
US
Modified natural cycle, Programmed cycle
JHSPH Center for Clinical Trials
Pregnancy Related, Pre-Eclampsia
04/25
08/25
ACTION-1, NCT05477576 / 2022-000507-12: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting
3
288
Europe, Canada, US, RoW
RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide
RayzeBio, Inc., RayzeBio, Inc.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
12/25
07/28
NCT01761929: 5 Fraction Stereotactic Body Radiation Therapy for Oligometastases Regimen, for Extra-Cranial Oligometastases

Completed
2
138
Canada
Radiation: 50Gy in 5 fr (max) to 25 Gy in 5 fr (min). Dose adapted to deliver the highest dose level while respecting normal tissue tolerance
University Health Network, Toronto, Princess Margaret Hospital, Canada
Solid Tumors With Oligometastatic Spread
02/23
02/23
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Recruiting
2
270
Europe, Canada, US, RoW
Buloxibutid, C21, Placebo
Vicore Pharma AB, Population Services International
Idiopathic Pulmonary Fibrosis (IPF)
02/27
03/27
NCT04467515: A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer

Terminated
1/2
13
Canada, US
CAM-H2
Precirix
Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
12/23
12/23
NCT01428895: Femoral Bone Metastases

Recruiting
N/A
180
Canada
Surgery Alone, Combined Surgery and Radiation therapy
University Health Network, Toronto
Cancer, Metastatic Malignant Neoplasm to Femur, Risk of Fracture
02/25
02/25
S-C-PATHY, NCT06390657: Radiotherapy Treatment Planning Comparison Using SBRT-PATHY (Photons) Versus CARBON-PATHY for Unresectable Bulky Tumors

Not yet recruiting
N/A
20
Europe
Planning CT, MRI
EBG MedAustron GmbH, The Princess Margaret Cancer Foundation
Cancer
12/25
12/25
MDS & PRRT, NCT06510868: Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy

Not yet recruiting
N/A
45
Canada
Peptide receptor radionuclide therapy (PRRT), Blood collection
University Health Network, Toronto
Myelodysplastic Syndrome, Acute Myeloid Leukemia
04/28
06/29
NCT01279408: Observing Patients With Palliative Asymptomatic Centrally Located Advanced Non-small Cell Lung Carcinoma (NSCLC)

Active, not recruiting
N/A
46
Canada
None: Questionnaire Study
University Health Network, Toronto
Non-small Cell Lung Carcinoma
11/28
11/28
Kuruvilla, John
NCT02436707: Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Recruiting
2
320
Canada
Ibrutinib, Rituximab, Gemcitabine, Dexamethasone, Cisplatin, Mesna, Cyclophosphamide, Etoposide, G-CSF, Selinexor
Canadian Cancer Trials Group, Janssen, LP, Roche Pharma AG, Karyopharm Therapeutics Inc
Lymphoma
12/25
12/26
NCT05180097: Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Recruiting
2
84
Canada, RoW
Gemcitabine, Dexamethasone, Cisplatin, Brentuximab vedotin, Pembrolizumab
Canadian Cancer Trials Group, Merck Sharp & Dohme LLC, Seagen Inc., Australasian Leukaemia and Lymphoma Group
Hodgkin Lymphoma
06/25
06/26
ZeTA, NCT06167785: A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T

Not yet recruiting
2
76
NA
Tislelizumab, Zanubrutinib, Tislelizumab + Zanubrutinib
University Health Network, Toronto
Large B-cell Lymphoma
12/25
12/27
GRAIL, NCT06050694: Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL

Not yet recruiting
2
40
Canada
glofitamab
University Health Network, Toronto
Diffuse Large B Cell Lymphoma (DLBCL)
11/25
11/27
KEsTREL-01, NCT04510636: Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

Recruiting
2
37
Canada
Pembrolizumab, KEYTRUDA, Bendamustine Hydrochloride, TREANDA
University Health Network, Toronto
Classical Hodgkin Lymphoma, Relapsed Cancer, Refractory Cancer
06/26
06/26
CARBON, NCT04035434: A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies

Terminated
1/2
62
Europe, Canada, US, RoW
CTX110
CRISPR Therapeutics AG
B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL
10/24
10/24
NCT04836195: Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma

Recruiting
1
60
Canada
PCLX-001
Pacylex Pharmaceuticals, Ozmosis Research Inc.
B-cell Non Hodgkin Lymphoma, Advanced Solid Tumor
10/24
12/24
NCT06208735: CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

Recruiting
1
24
Canada
CLIC-2201, Autologous CD22 targeting CAR-T cells
British Columbia Cancer Agency
B-Cell Leukemia, Non-Hodgkin's Lymphoma, B-cell Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Mantle Cell Lymphoma, B-cell Lymphoma
08/26
08/27
ODIN, NCT05950802: Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta

Recruiting
1
40
Canada
Cyclophosphamide, cytoxin, neosar, TLI
University Health Network, Toronto
DLBCL - Diffuse Large B Cell Lymphoma
06/25
06/27
LOKI, NCT06003179: Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah

Withdrawn
1
40
Canada
Cyclophosphamide, Cytoxan, neosar, TLI, Fludarabine
University Health Network, Toronto
Lymphoma, Large B-Cell, Diffuse
11/26
11/28
NCT06120504: A Safety Study of SGN-35T in Adults With Advanced Cancers

Active, not recruiting
1
18
Europe, Canada, US
SGN-35T
Seagen Inc.
Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
06/27
04/30
Sridhar, Srikala
TRANCE, NCT03432949: Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC

Active, not recruiting
4
24
Canada
Dexamethasone plus Radium-223, Dexamethasone, Baycadron
University Health Network, Toronto, Bayer
Metastatic Prostate Cancer
09/23
07/24
MAIN-CAV, NCT05092958: Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, Study

Active, not recruiting
3
654
Canada, US
Avelumab, Bavencio, MSB 0010718C, MSB-0010718C, MSB0010718C, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI)
Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis and Ureter Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8
12/25
12/25
KEYNOTE-D74, NCT05911295: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Recruiting
3
400
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, pembrolizumab, KEYTRUDA®, gemcitabine, Gemzar, cisplatin, carboplatin
Seagen Inc., RemeGen Co., Ltd., Merck Sharp & Dohme LLC
Urothelial Carcinoma
06/26
04/29
NCT03391479: A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy

Recruiting
2
24
Canada
Avelumab, Best Supportive Care
University Health Network, Toronto
Penile Cancer, Advanced Cancer, Metastatic Cancer
12/24
12/24
NCT06129084: A Study to Compare the Results of FGFR Testing by Either CtDNA Blood Testing or Standard Tumor Tissue Testing

Recruiting
N/A
260
Canada
FGFR Testing
Bernie Eigl, Vancouver Prostate Centre, Lady Davis Institute, Bladder Cancer Canada
Metastatic Bladder Cancer, Metastatic Urothelial Carcinoma
03/25
05/25
PET MUSE, NCT02462239: Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging

Completed
N/A
292
Canada
Whole-body FDG PET-CT, PET-CT imaging
Ontario Clinical Oncology Group (OCOG), Cancer Care Ontario
Muscle-invasive Bladder Cancer
03/24
11/24
TOPCOP3, NCT05582772: TOward a comPrehensive Supportive Care Intervention for Older Men With Metastatic Prostate Cancer

Recruiting
N/A
168
Canada
GA+M Intervention, Geriatric assessment and management, RSM intervention, Remote symptom monitoring, GA+RSM intervention, Geriatric assessment and remote symptom monitoring
University Health Network, Toronto
Metastatic Prostate Cancer
02/27
02/27
Liu, Geoffrey
OCELOT, NCT04335292: Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge

Recruiting
2
200
Canada
Osimertinib First-Line, Platinum + Pemetrexed Chemotherapy Second-Line, Osimertinib Third-Line
Mark Vincent, AstraZeneca
Non-Small Cell Lung Cancer
06/26
06/27
ARROS-1, NCT05118789 / 2021-002477-26: A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement

Recruiting
1/2
359
Europe, Canada, Japan, US, RoW
NVL-520
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
10/25
10/26
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation

Recruiting
1/2
470
Europe, Canada, Japan, US, RoW
NVL-655
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
02/26
03/26
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
EXTRACT, NCT05207423: A Chart Review Study of Adults With Advanced NSCLC

Completed
N/A
179
Europe, Canada, RoW
Takeda
Non-small Cell Lung Cancer (NSCLC)
02/23
02/23
NCT04146064: Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response

Recruiting
N/A
425
Canada
Breathprint analysis and patient-reported outcomes
University Health Network, Toronto, University of Amsterdam
NSCLC, Melanoma, Kidney Cancer, Urothelial Carcinoma, Head and Neck Cancer
05/24
05/24
CARMA-BROS, NCT04151342: CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)

Recruiting
N/A
1000
Canada
Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents., Patient-reported outcomes (PROs)
University Health Network, Toronto, Takeda Canada, Inc., Applied Health Research Centre, Programs for Assessment of Technology in Health Research Institute, AstraZeneca, Amgen, Bayer, AnHeart Therapeutics Inc.
Cancer, Malignancies Multiple, Malignant Solid Tumor, Cancer, Therapy-Related, Molecular Sequence Variation, Genetic Alteration, Gene Fusion, Receptor Tyrosine Kinase Gene Mutation, RTK Family Gene Mutation, Ras (Kras or Nras) Gene Mutation
12/25
12/25
NCT05376891: Met Non Small Cell Cancer Registry (MOMENT)

Recruiting
N/A
700
Europe, Canada, US, RoW
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Cancer
03/27
03/27

Download Options